Showing results (151-160 of 167) with videos related to

Sort By:
Pageof 17
Gynecologic Oncology|October 9, 2020
Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and cold knife cone biopsyPaul A Cohen, Yee Leung, Lyndal Anderson, et al.
The Lancet. Oncology|April 20, 2023
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trialLinda R Mileshkin, Kathleen N Moore, Elizabeth H Barnes, et al.
Ebiomedicine|October 17, 2021
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinaseHui-Ming Lin, Blossom Mak, Nicole Yeung, et al.
European Urology|April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901)Louise Emmett, Nathan Papa, Oliver Sartor, et al.
British Journal of Cancer|July 8, 2026
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trialKatrin M Sjoquist, Alexander Dobrovic, Kristy P Robledo, et al.
The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
The New England Journal of Medicine|June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerIan D Davis, Andrew J Martin, Martin R Stockler, et al.
European Urology|May 25, 2021
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapyChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
The Lancet. Oncology|December 3, 2023
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
Pageof 17